Stephen Pickup
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen Pickup has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Cynthia Clendenin
University of Pennsylvania Perelman School of Medicine, Abramson Cancer Center, Philadelphia, USA
32 shared publications - Emma E. Furth
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
32 shared publications - Fang Liu
University of Pennsylvania 5 Center for Clinical Epidemiology and Biostatistics Philadelphia, Pennsylvania
32 shared publications - Hoon Choi
University of Pennsylvania 1 Department of Radiology Philadelphia, Pennsylvania
32 shared publications - Mamta Gupta
University of Pennsylvania 1 Department of Radiology Philadelphia, Pennsylvania
32 shared publications - Mark Rosen
University of Pennsylvania 1 Department of Radiology Philadelphia, Pennsylvania
32 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Purpose:A pilot clinical trial (NCT03519308) was conducted to evaluate perioperative chemotherapy [nab-paclitaxel, gemcitabine, and cisplatin (NGC)] plus nivolumab, with or without synthetic vitamin D (paricalcitol) in resectable pancreatic ductal adenocarcinoma (PDAC). Preclinical studies were designed with statistical power to match the experimental regimen and compare NGC only with NGC plus synthetic vitamin D [calcipotriol (Cal)] or losartan (Losa; an antihypertensive medication). Materials and Methods:Molecular subtyping was applied to enroll patients with epithelial subtype PDAC. Genetically engineered PDAC models (KrasG12D;Trp53R172H;Pdx1-Cre mice, N = 140) were randomized to NGC only and combined therapies. Multiparametric MRI and molecular profiling were integrated to assess treatment-induced effects on stroma, including capillary perfusion and density, matrix collagen content, fibroblast activation protein (FAP) levels and transcriptome changes. Results:The clinical trial had limited enrollment (N = 3) but confirmed the safety and feasibility of weekly paricalcitol infusion in combination with multiagent chemotherapy. NGC chemotherapy had a profound impact on stroma, inducing a remarkable reduction in FAP levels accompanied by a significant increase in matrix collagen content; chemotherapy also activated epithelial–mesenchymal transition (EMT) and significantly reduced blood perfusion and capillary density, resulting in features of chemoresistance. Combining NGC with stromal-targeting agents—Cal or Losa—diminished EMT and partially restored perfusion through distinct mechanisms: Cal activates the vitamin D receptor to reprise a quiescent stroma, whereas Losa suppresses TGFβ to increase lymphocyte infiltration. Conclusions:These findings support further investigations of stromal-directed combination strategies to overcome chemotherapy-induced resistance of PDAC. Dynamic contrast-enhanced MRI may provide a valuable platform to monitor stromal adaptations to therapy in vivo. Significance:Results from co-clinical trials integrating MRI and molecular profiling provide a translational rationale for investigating stromal-directed combination strategies in PDAC. These approaches may help preserve chemosensitivity, counteract chemotherapy-induced stromal and vascular remodeling, and overcome adaptive resistance mechanisms that limit durable treatment response.
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Purpose:A pilot clinical trial (NCT03519308) was conducted to evaluate perioperative chemotherapy [nab-paclitaxel, gemcitabine, and cisplatin (NGC)] plus nivolumab, with or without synthetic vitamin D (paricalcitol) in resectable pancreatic ductal adenocarcinoma (PDAC). Preclinical studies were designed with statistical power to match the experimental regimen and compare NGC only with NGC plus synthetic vitamin D [calcipotriol (Cal)] or losartan (Losa; an antihypertensive medication). Materials and Methods:Molecular subtyping was applied to enroll patients with epithelial subtype PDAC. Genetically engineered PDAC models (KrasG12D;Trp53R172H;Pdx1-Cre mice, N = 140) were randomized to NGC only and combined therapies. Multiparametric MRI and molecular profiling were integrated to assess treatment-induced effects on stroma, including capillary perfusion and density, matrix collagen content, fibroblast activation protein (FAP) levels and transcriptome changes. Results:The clinical trial had limited enrollment (N = 3) but confirmed the safety and feasibility of weekly paricalcitol infusion in combination with multiagent chemotherapy. NGC chemotherapy had a profound impact on stroma, inducing a remarkable reduction in FAP levels accompanied by a significant increase in matrix collagen content; chemotherapy also activated epithelial–mesenchymal transition (EMT) and significantly reduced blood perfusion and capillary density, resulting in features of chemoresistance. Combining NGC with stromal-targeting agents—Cal or Losa—diminished EMT and partially restored perfusion through distinct mechanisms: Cal activates the vitamin D receptor to reprise a quiescent stroma, whereas Losa suppresses TGFβ to increase lymphocyte infiltration. Conclusions:These findings support further investigations of stromal-directed combination strategies to overcome chemotherapy-induced resistance of PDAC. Dynamic contrast-enhanced MRI may provide a valuable platform to monitor stromal adaptations to therapy in vivo. Significance:Results from co-clinical trials integrating MRI and molecular profiling provide a translational rationale for investigating stromal-directed combination strategies in PDAC. These approaches may help preserve chemosensitivity, counteract chemotherapy-induced stromal and vascular remodeling, and overcome adaptive resistance mechanisms that limit durable treatment response.
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
DCE metric over time and posttreatment MVD in KPC tumors. Plots of Ktrans at baseline and day 7, CD31-stained micrographs, and MVD from treatment arms in the matched trial (A and B) and chemo–stromal trial (C and D). CD31-positive cells are stained brown. Sample size (MRI/IHC): CNTRL (control, n = 6/11), Cal (n = 3/9), NGC + Cal + PD-L1 (n = 3/10), NGC (n = 8/10), NGC + Cal (n = 6/8), and NGC + Losa (n = 7/22). Scale bars, 70 μm. ##, P < 0.01; two-tailed t test. *, P < 0.05; **, P < 0.01; Mann–Whitney test with two-tailed P value (details in “Statistical analysis”).
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
DCE metric over time and posttreatment MVD in KPC tumors. Plots of Ktrans at baseline and day 7, CD31-stained micrographs, and MVD from treatment arms in the matched trial (A and B) and chemo–stromal trial (C and D). CD31-positive cells are stained brown. Sample size (MRI/IHC): CNTRL (control, n = 6/11), Cal (n = 3/9), NGC + Cal + PD-L1 (n = 3/10), NGC (n = 8/10), NGC + Cal (n = 6/8), and NGC + Losa (n = 7/22). Scale bars, 70 μm. ##, P < 0.01; two-tailed t test. *, P < 0.05; **, P < 0.01; Mann–Whitney test with two-tailed P value (details in “Statistical analysis”).
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Tumor size change in preclinical trials. Waterfall plots of individual tumors and tumor size change on day 14 in the matched trial (A and B) and chemo–stromal trial (C and D). For each treatment group, a regression index is calculated as the percentage of tumors in which sizes were reduced compared with baseline (bars of negative values in waterfall plots), whereas a progression index is calculated as the percentage of tumors that doubled their volume (marked by the red dotted line). Sample size: control (CNTRL), n = 12; Cal, n = 11; NGC + Cal + PD-L1, n = 18; NGC + Cal + IgG, n = 9; NGC, n = 36; NGC + Cal, n = 21; NGC + LOSA, n = 18. *, P < 0.05; ****, P < 0.0001; Mann–Whitney test with two-tailed P value. ##, P < 0.01; ###, P < 0.001; ####, P < 0.0001; two-tailed t test (details in the “Statistical analysis” section).
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Tumor size change in preclinical trials. Waterfall plots of individual tumors and tumor size change on day 14 in the matched trial (A and B) and chemo–stromal trial (C and D). For each treatment group, a regression index is calculated as the percentage of tumors in which sizes were reduced compared with baseline (bars of negative values in waterfall plots), whereas a progression index is calculated as the percentage of tumors that doubled their volume (marked by the red dotted line). Sample size: control (CNTRL), n = 12; Cal, n = 11; NGC + Cal + PD-L1, n = 18; NGC + Cal + IgG, n = 9; NGC, n = 36; NGC + Cal, n = 21; NGC + LOSA, n = 18. *, P < 0.05; ****, P < 0.0001; Mann–Whitney test with two-tailed P value. ##, P < 0.01; ###, P < 0.001; ####, P < 0.0001; two-tailed t test (details in the “Statistical analysis” section).
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Matrix collagen level in KPC tumors. Micrographs of Sirius red (SR) staining of the tumor and posttreatment matrix collagen level estimated by %SR positive are presented for treatment arms in the matched trial (A) and the chemo–stromal trial (B). Time course of MTR in matched treatment arms (top, C) and the chemo–stromal trial (bottom, C). Correlation between MTR and cell density of the tumor (D). Correlation between matrix collagen and MVD (E). Scale bars, 70 μm. Sample size: control (CNTRL), n = 15; Cal, n = 9; NGC + Cal + PD-L1, n = 9; NGC, n = 16; NGC + Cal, n = 15; and NGC + Losa, n = 22. **, P < 0.01; Mann–Whitney test with two-tailed P value (details in the “Statistical analysis” section). The representative H&E image shown for the control group is from the same control tumor specimen shown in Fig. 3 but corresponds to a different tumor region, as indicated by the boxed area in the thumbnail image.
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Matrix collagen level in KPC tumors. Micrographs of Sirius red (SR) staining of the tumor and posttreatment matrix collagen level estimated by %SR positive are presented for treatment arms in the matched trial (A) and the chemo–stromal trial (B). Time course of MTR in matched treatment arms (top, C) and the chemo–stromal trial (bottom, C). Correlation between MTR and cell density of the tumor (D). Correlation between matrix collagen and MVD (E). Scale bars, 70 μm. Sample size: control (CNTRL), n = 15; Cal, n = 9; NGC + Cal + PD-L1, n = 9; NGC, n = 16; NGC + Cal, n = 15; and NGC + Losa, n = 22. **, P < 0.01; Mann–Whitney test with two-tailed P value (details in the “Statistical analysis” section). The representative H&E image shown for the control group is from the same control tumor specimen shown in Fig. 3 but corresponds to a different tumor region, as indicated by the boxed area in the thumbnail image.
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
FAP in human PDAC surgical specimens and KPC tumors. FAP-stained micrographs and percentage of FAP staining in surgically resected PDAC tumors from patients who had NAC (n = 10) or were untreated (n = 10) before surgery (A). FAP-stained micrographs and quantifications from KPC tumors harvested after treatment from mice enrolled in the matched trial (B) and chemo–stromal trial (C). Sample size of KPC model: control (CNTRL), n = 21; Cal, n = 13; NGC + Cal + PD-L1, n = 10; NGC, n = 13; NGC + Cal, n = 9; and NGC + Losa, n = 13. Scale bars, 70 μm or as indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Mann–Whitney test with two-tailed P value (details in the “Statistical analysis” section).
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
FAP in human PDAC surgical specimens and KPC tumors. FAP-stained micrographs and percentage of FAP staining in surgically resected PDAC tumors from patients who had NAC (n = 10) or were untreated (n = 10) before surgery (A). FAP-stained micrographs and quantifications from KPC tumors harvested after treatment from mice enrolled in the matched trial (B) and chemo–stromal trial (C). Sample size of KPC model: control (CNTRL), n = 21; Cal, n = 13; NGC + Cal + PD-L1, n = 10; NGC, n = 13; NGC + Cal, n = 9; and NGC + Losa, n = 13. Scale bars, 70 μm or as indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Mann–Whitney test with two-tailed P value (details in the “Statistical analysis” section).
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Single-cell RNA-seq analysis of KPC tumors. Fraction of epithelial versus basal/mesenchymal subtype cancer cells in tumors after specified treatment (A). Violin plots of the basal subtype signature gene Fn1 and the epithelial signature gene Tff1 expression of samples (B). Gene set enrichment analysis revealed EMT activation after NGC but not after NGC + Cal or NGC + Losa treatment (C). Sample size: Two tumors from each treatment group were combined for single-cell RNA-seq analysis. ES, enrichment score; NES, normalized enrichment score.
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Single-cell RNA-seq analysis of KPC tumors. Fraction of epithelial versus basal/mesenchymal subtype cancer cells in tumors after specified treatment (A). Violin plots of the basal subtype signature gene Fn1 and the epithelial signature gene Tff1 expression of samples (B). Gene set enrichment analysis revealed EMT activation after NGC but not after NGC + Cal or NGC + Losa treatment (C). Sample size: Two tumors from each treatment group were combined for single-cell RNA-seq analysis. ES, enrichment score; NES, normalized enrichment score.
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Figure S1. Design of clinical trial (NCT03519308).
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Figure S1. Design of clinical trial (NCT03519308).
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Figure S3. Time course of tumor volume in KPC mice enrolled in preclinical trials and odds ratio analysis.
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Figure S3. Time course of tumor volume in KPC mice enrolled in preclinical trials and odds ratio analysis.
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Figure S10. Transcriptome changes in cancer associated fibroblasts, CAFs after chemotherapy and its combination with calcipotriol or losartan.
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Figure S10. Transcriptome changes in cancer associated fibroblasts, CAFs after chemotherapy and its combination with calcipotriol or losartan.
- Open Access
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Figure S2. Exploratory results from NCT03519308: Full-mount histology of surgically resected tumors, tumor ADC values and cellularity.
- 25 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Figure S2. Exploratory results from NCT03519308: Full-mount histology of surgically resected tumors, tumor ADC values and cellularity.